

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

CHRISTOPHER R. COGLE,^a BART L. SCOTT,^b THOMAS BOYD,^c GUILLERMO GARCIA-MANERO^d

^aDivision of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA;

^bFred Hutchinson Cancer Research Center, Seattle, Washington, USA; ^cNorth Star Lodge Cancer Center, Yakima, Washington, USA;

^dDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words. Leukemia • Myeloid • Acute • Myelodysplastic syndromes • Azacitidine

ABSTRACT

The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid malignancies characterized by multilineage cytopenias, recurrent cytogenetic abnormalities, and risk of progression to acute myeloid leukemia (AML). AML, which can occur de novo as well as secondary to MDS, is characterized by malignant clones of myeloid lineage in the bone marrow and peripheral blood, with dissemination into tissues. The cytidine nucleoside analog and epigenetic modifier azacitidine is approved in the U.S. for the treatment of all French-American-British subtypes of MDS and in many countries for the treatment of AML with 20%–30% blasts and multilineage dysplasia according to the World Health Organization classification. Benefits of azacitidine treatment of patients with AML with >30% blasts have also been shown in a recent phase III trial. Oral administration of azacitidine may

enhance patient convenience, eliminate injection-site reactions, allow for alternative dosing and scheduling, and enable long-term treatment. Phase I studies with oral azacitidine (CC-486) have shown biological activity, clinical responses, and tolerability in patients with MDS and AML. Extended dosing schedules of oral azacitidine (for 14 or 21 days of 28-day cycles) are currently under investigation as frontline therapy in patients with lower risk MDS, as maintenance therapy for patients with AML not eligible for stem cell transplant, and as maintenance therapy for patients with MDS or AML following stem cell transplant. This review presents clinical data supporting the use of injectable azacitidine in MDS and AML and examines the rationale for and results of the clinical development of oral azacitidine. *The Oncologist* 2015;20:1404–1412

Implications for Practice: Injectable azacitidine can prolong survival, reduce transfusions, and improve quality of life compared with conventional care regimens in patients with higher-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). An oral formulation improves convenience and eliminates injection-site reactions but also enables testing of novel, longer term, low-dose schedules that may enhance therapeutic activity of azacitidine by increasing exposure to cycling malignant cells. In early phase trials, oral azacitidine (CC-486) in extended dosing regimens was biologically and clinically active in patients with MDS and AML. Oral azacitidine is being further evaluated in an ongoing phase III program.

INTRODUCTION

The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid malignancies arising from a stem cell source and characterized by multiple genetic abnormalities and subclonal architectures [1–4]. There is considerable heterogeneity in genetic mutations among patients with MDS that may explain the diversity of clinical presentations that differ in the numbers and depths of cytopenias, risks toward progression to acute myeloid leukemia (AML), responses to treatment, and survival times [5–8]. Gene mutations affecting epigenetic chemical modifications, such as mutations in *TET2* and *DNMT3A*, are among the most common in MDS [9–11].

MDS is primarily a disease of older adults, and advanced age at diagnosis is associated with decreased overall survival (OS) [12, 13]. The reported incidence rate of MDS overall is 5.70 per 100,000 persons in the U.S. [14] and 1.82 per 100,000 persons in Europe [15]. In patients aged ≥65 years, the incidence rate is higher, at 12.97 per 100,000 persons or higher in the U.S. [14] and 5 per 100,000 persons or higher in Europe [15]; however, these are likely underestimates of true incidence. Large numbers of MDS cases go unreported by state cancer registries due to difficulties in disease diagnosis, underappreciation of MDS as a malignancy, under-reporting by

Correspondence: Christopher R. Cogle, M.D., University of Florida, Medicine/Hematology and Oncology, 1600 SW Archer Road, Box 100278, Gainesville, Florida 32610, USA. Telephone: 352-273-7493; E-Mail: christopher.cogle@medicine.ufl.edu Received April 22, 2015; accepted for publication August 21, 2015; published Online First on October 13, 2015. ©AlphaMed Press 1083-7159/2015/\$20.00/0 <http://dx.doi.org/10.1634/theoncologist.2015-0165>

CELGENE 2073

APOTEX v. CELGENE

IPR2023-00512

©AlphaMed Press 2015

outpatient clinics, changing guidelines for defining MDS, and lack of resources [15–18]. When accounting for the uncaptured cases, MDS is one of the most common hematologic malignancies.

The current MDS treatment paradigm is based on prognostic risk assessment [8, 13, 19, 20]. Patients at lower risk for early death or evolution to AML are treated with agents to primarily reduce or eliminate blood transfusions and to improve quality of life (QOL), whereas patients at higher risk for early death or AML progression are generally treated with more intensive therapies aiming to induce disease remission and lengthen survival [8, 21, 22].

AML is a multigenetic malignancy characterized by malignant clones and subclones of myeloid lineage in the bone marrow and peripheral blood, with dissemination into tissues [23–25]. It is the most common acute leukemia in adults [23], with an estimated incidence rate of 4.06 per 100,000 persons in the U.S. [14] and 3.62 per 100,000 persons in Europe [15]. Similar to MDS, AML incidence increases with advancing age, with incidence rates in the U.S. and Europe of 10 per 100,000 persons or higher for patients aged ≥ 65 years [14, 15]. AML has a poor prognosis, particularly in older patients and those with adverse disease characteristics (e.g., secondary AML, complex cytogenetic abnormalities, or *FLT3* mutation) [26–30]. Three-quarters of patients with AML die within 5 years of diagnosis, and survival decreases with increasing age [26]. Disease characteristics and performance status are closely considered when evaluating patient eligibility for treatment with intensive therapies (e.g., induction followed by consolidation chemotherapy or stem cell transplant [SCT]) versus low-intensity options such as injectable azacitidine or decitabine [27–29, 31–33].

AZACITIDINE FOR INJECTION

Azacitidine is a cytidine nucleoside analog with a substitution of the carbon at position 5 with nitrogen that prevents methylation by covalently binding DNA methyltransferases [32, 34] (Fig. 1). The epigenetic modifier azacitidine is incorporated into DNA and RNA [34, 35]. Antileukemic effects of azacitidine are thought to include direct cytotoxicity from inhibition of protein synthesis and DNA damage and re-expression of aberrantly silenced tumor suppressor genes due to DNA hypomethylation [32, 34–37]. Azacitidine is approved in the U.S. for the treatment of all French-American-British (FAB) subtypes of MDS [32] and is approved in many countries (e.g., European Union, Australia, Republic of Korea, Taiwan) for patients not eligible for SCT with intermediate-2 (Int-2) and high-risk MDS according to the International Prognostic Scoring System (IPSS) and patients with AML with 20%–30% blasts and multilineage dysplasia according to World Health Organization (WHO) classification [38]. Azacitidine is also approved by the U.S. Food and Drug Administration for chronic myelomonocytic leukemia (CMML) and by the European Medicines Agency for “CMML with 10%–29% marrow blasts without myeloproliferative disorder.”

The approved dosing of azacitidine is 75 mg/m² per day on days 1–7 of 28-day cycles [32, 38]. Alternative dosing schedules have been explored, including 5-day and 5-2-2-day dosing regimens to avoid weekend administration [39–41], but are not approved. Although hematologic improvement (HI) with




Figure 1. Structure of azacitidine. Substitution of carbon at position 5 with nitrogen prevents DNA methylation [34].

5-day dosing in patients with MDS is compelling, clinicians should not extrapolate data for injectable azacitidine based on the approved 7-day dosing regimen, especially in patients with higher risk MDS. The 5-day and 5-2-2-day alternate regimens require more rigorous testing.

Initial approval was based primarily on results from two phase III studies. CALGB-9221 was a phase III multicenter randomized controlled trial of subcutaneous (s.c.) azacitidine (75 mg/m² per day on days 1–7 in 28-day cycles; $n = 99$) versus best supportive care (BSC; $n = 92$) in patients with all FAB MDS subtypes [42]. In this trial, the overall response rate (ORR) with azacitidine was significantly improved versus BSC (60% vs. 5%, $p < .0001$) [42]. Response rates to azacitidine were comparable in patients with lower and higher risk MDS [42]. Myelosuppression was the most common toxicity, and adverse events (AEs) were generally transient, resolving before the next treatment cycle [42].

AZA-001 was a phase III multicenter randomized controlled trial of s.c. azacitidine (75 mg/m² per day on days 1–7 in 28-day cycles) versus conventional care regimens (CCR: BSC, low-dose cytarabine [LDAC], or intensive chemotherapy [IC]) in patients with IPSS-defined higher risk (Int-2 or high-risk) MDS ($N = 358$) [43]. Azacitidine treatment resulted in significantly longer OS (median: 24.5 vs. 15 months; $p = .0001$), higher rates of hematologic response ($p = .0001$) and HI ($p < .0001$) assessed by International Working Group (IWG) 2000 criteria [21], and longer durations of response (median: 13.6 vs. 5.2 months; $p = .0002$) versus CCR [43]. Azacitidine prolonged OS compared with CCR regardless of IPSS cytogenetic risk group [43].

A multivariate analysis of AZA-001 showed that achievement of hematologic response or HI (IWG 2000 criteria [21]) was associated with improved OS with azacitidine treatment [44], and patients who achieved a hematologic response to azacitidine had significantly prolonged OS and reduced risk of death versus patients who achieved a response to CCR [44]. In addition, stable disease or achievement of complete response (CR), marrow CR (mCR), partial response (PR) or HI (IWG 2003 [45] and 2006 criteria [22]) with alternative dosing schedules of azacitidine has been shown to significantly reduce the risk of death versus disease progression ($p < .001$) [39].

In the AZA-001 study, the median time to first response with azacitidine was 2 cycles (range: 1–16), with 91% of responding patients achieving first response within 6 cycles and all but 1 achieving first response by cycle 12 [46]. Continued treatment improved response quality in 48% of patients [46], with a median of 3 cycles from first to best

response. By cycle 12, 92% of responding patients achieved their best response. Based on this experience, some clinicians have advised administering at least six cycles of azacitidine [47], and the National Comprehensive Cancer Network guidelines for MDS recommend at least four to six cycles before assessing for treatment failure [8]. Assessments for treatment failure include evaluation of peripheral blood, bone marrow aspiration or biopsy, cytogenetic testing, and genetic studies. If response is achieved, azacitidine is typically continued until disease progression, unacceptable toxicity, or definitive therapy with SCT. If no response is achieved after six cycles of azacitidine, then prognosis is generally poor [48, 49]. Small case series have shown that decitabine treatment after azacitidine failure yields modest responses (ORR: 0%–28%) that are generally short lived [48, 50–53]; however, this is not currently standard treatment practice. The current standard of care for patients with MDS who have not responded after at least six cycles of azacitidine treatment is to consider clinical trials [48, 49] or proceed with SCT [51].

The most common grade 3/4 AEs with azacitidine treatment in patients with MDS in the AZA-001 trial were cytopenias [43], and most were transient and resolved during therapy [54]. The highest rates of AEs reported with azacitidine in AZA-001 occurred during cycles 1–2, with decreased frequency with continued treatment. Median duration of hematologic AEs was 14–16 days.

Azacitidine has also been investigated for the treatment of patients with AML. In a subanalysis of AZA-001 of low-blast-count AML (20%–30% blasts; $n = 113$), the 2-year OS rate for patients treated with azacitidine was 50%, and the median OS was 24.5 months compared with 16.0 months for patients treated with CCR ($p = .005$) and 16.4 months for patients not preselected to receive IC (BSC or LDAC; $p = .004$) [31]. Survival benefits with azacitidine may not require CR because CR rates were similar for azacitidine versus CCR (18% vs. 16%; $p = .8$), whereas rates of red blood cell transfusion independence (RBC-TI) were significantly higher with azacitidine (41% vs. 18%; $p = .04$) [31].

Recently, the global phase III randomized open-label AZA-AML-001 study of azacitidine (75 mg/m² per day on days 1–7 in 28-day cycles) versus CCR extended these findings in patients aged ≥ 65 years with newly diagnosed AML with $>30\%$ blasts ($N = 488$) [55]. Azacitidine treatment demonstrated a clinically meaningful improvement in median OS of 10.4 months versus 6.5 months with CCR ($p = .1009$). Azacitidine significantly improved 1-year survival: 46.5% versus 34.2% with CCR, a 12.3% difference (95% confidence interval: 3.5%–21.0%). In patients who did not achieve CR (IWG 2003 criteria [45]), median OS was prolonged from 6.9 months with azacitidine versus 4.2 months with CCR ($p = .0170$).

The safety profile of azacitidine for the treatment of AML was consistent with previous observations [31, 43, 55]. The most common grade 3/4 hematologic AEs were cytopenias, which occurred more frequently during earlier treatment cycles [31, 55].

RATIONALE FOR ORAL ADMINISTRATION OF AZACITIDINE

Oral administration of azacitidine avoids injection-site reactions and may enhance patient convenience compared

with an injectable formulation [56, 57]. It allows for the evaluation of alternative doses and schedules, including extended dosing schedules. Early trials with injectable azacitidine showed decreased toxicity and increased efficacy at lower doses over several days versus a single higher dose [58–61]. In addition, in patients with MDS, continued treatment with s.c. azacitidine was shown to improve response quality [46].

The benefits of extended azacitidine dosing and long-term treatment are likely related to the impact on hypomethylation. Hypomethylating effects are cell cycle dependent [62], and serial cycles of DNA replication are needed to induce hypomethylation [63, 64]. Extensive demethylation requires prolonged drug exposure [63]. Due to the short plasma half-life of azacitidine [34, 38] and cell cycle-restricted DNA incorporation [62], extended dosing schedules enabled by oral administration have the potential to enhance clinical activity of azacitidine by increasing exposure to cycling malignant cells.

CLINICAL INVESTIGATIONS WITH ORAL AZACITIDINE (CC-486)

Pilot Study of Oral Azacitidine

The bioavailability and safety of oral azacitidine was initially studied in an open-label, pharmacokinetic (PK), and feasibility pilot study of patients with MDS, leukemia, or solid tumors [56]. Four patients received 60- or 80-mg single doses of oral azacitidine. All four patients had measurable plasma concentrations, allowing for comparison with historical s.c. azacitidine PK data. The 80-mg oral azacitidine dose had mean bioavailability of 17% of that of s.c. azacitidine [56, 65]. No severe drug-related toxicities were observed, and results from this pilot study led to the development of a phase I study of oral azacitidine.

Dose-Finding Study of Oral Azacitidine

Because of the demonstrated safety and efficacy of injectable azacitidine in patients with MDS and AML [32, 38], the oral azacitidine phase I program initially focused on these patient populations. AZA PH US 2007 CL 005 was a phase I open-label dose-escalation study that evaluated the safety, PK, and pharmacodynamics (PD) of oral azacitidine in patients with MDS, CMML, or AML [66]. This trial had two parts (Fig. 2) [57, 66]: In part 1, 41 patients (71% MDS, 10% CMML, 20% AML) received 7-day dosing of s.c. azacitidine for a single 28-day cycle, followed by oral azacitidine for 7 days of 28-day cycles (cycles 2 and beyond; Table 1). During cycles 1 and 2, PK (days 1 and 7) and PD (days 1, 3, 8, 15, 22, and 28) profiles were assessed.

The maximum tolerated dose (MTD) of oral azacitidine was 480 mg once daily (QD) for 7 days [66]. Dose-limiting toxicities (DLTs) were reported in 2 of 3 patients treated with oral azacitidine 600 mg QD for 7 days (1 grade 3 diarrhea and 1 grade 4 diarrhea despite medical intervention) with no other DLTs observed. Gastrointestinal AEs were the most common nonhematologic AEs and were primarily grade 1/2 and manageable [66] with gastric acid-reducing agents, antiemetics, and antidiarrheal




Figure 2. Trial schema for AZA PH US 2007 CL 005, the phase I trial of oral azacitidine (CC-486) in patients with myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia [67].
Abbreviations: BID, twice daily; QD, once daily; s.c., subcutaneous.

Table 1. Summary of clinical results from the expanded phase I study of oral azacitidine (CC-486) in patients with MDS and AML [66, 69, 71]

Variable	Dose-finding study in MDS, CMML, and AML [66]	Extended-dosing in patients with lower risk MDS [69]	Subset analysis: 7-day and extended dosing in patients with AML [71]	
Dosing	Cycle 1: s.c. AZA 75 mg/m ² QD × 7 days Cycles ≥2: CC-486 120–600 mg QD × 7 days	CC-486 300 mg QD × 14 or 21 days	Cycle 1: s.c. AZA 75 mg/m ² QD × 7 days Cycles ≥2: CC-486 120–600 mg QD × 7 days	CC-486 300 mg QD or 200 mg BID × 14 or 21 days
Patient population, n (%)	MDS: 29 (71) CMML: 4 (10) AML: 8 (20)	IPSS low-risk MDS: 15 (28) IPSS Int-1 risk MDS: 38 (72) RBC-TD: 30 (57) Platelet-TD: 4 (8)	De novo AML: 13 (57) Secondary AML: 10 (43) RBC-TD: 14 (61) Platelet-TD: 8 (35)	
Key safety data	MTD: 480 mg QD × 7 days DLTs: grade 3 or 4 diarrhea Most common grade 3/4 AEs: febrile neutropenia (20%), diarrhea (12%)	Most common AEs (any grade) were gastrointestinal in origin Most common grade 3/4 AEs: neutropenia (13%) 8 patients D/C due to AEs	Most common AEs (any grade) were gastrointestinal in origin Most common grade 3/4 AEs: febrile neutropenia (35%), pneumonia (17%), syncope (17%), nausea (13%) 6 patients D/C due to AEs	
Key efficacy data	First-line patients: 73% ORR, 56% any HI, 33% mCR Previously-treated patients: 35% ORR, 38% any HI, 67% mCR	300 mg QD × 14 days: 42% ORR, 27% any HI, 20% RBC-TI sustained 84 days 300 mg QD × 21 days: 37% ORR, 30% any HI, 33% RBC-TI sustained 84 days	38% ORR, 13% HI, 25% mCR, 13% mPR, 25% RBC-TI ^a	47% ORR, 27% HI, 40% RBC-TI, 17% platelet-TI, 33% mPR ^b

^aEight evaluable patients for each, except four evaluable patients for RBC-TI.
^bFifteen evaluable patients for ORR and HI, 10 evaluable patients for RBC-TI, 6 evaluable patients for platelet-TI, and 9 evaluable patients for mPR.
Abbreviations: AE, adverse event; AML, acute myeloid leukemia; AZA, azacitidine; BID, twice daily; CMML, chronic myelomonocytic leukemia; D/C, discontinued; DLT, dose-limiting toxicity; HI, hematologic improvement; Int-1, intermediate-1; IPSS, International Prognostic Scoring System; mCR, marrow complete response; mPR, marrow partial response; MDS, myelodysplastic syndromes; MTD, maximum tolerated dose; ORR, overall response rate; QD, once daily; RBC, red blood cell; s.c., subcutaneous; TD, transfusion dependence; TI, transfusion independence.

medications [67]. The most common (≥10%) grade 3/4 AEs were febrile neutropenia (20%), diarrhea (12%), and fatigue (10%). Notably, 4 of 8 patients with grade 3/4 febrile neutropenia had an absolute neutrophil count ≤500/μL at baseline [66]. Grade 3/4 nausea and vomiting were each reported in 7% of patients. Three patients discontinued due to an AE. The investigators of part 1 of the trial concluded that 7-day oral azacitidine dosing was clinically active (Tables 1, 2). Responses in patients treated with oral azacitidine as first-line therapy included a 73% ORR, 56% with any HI, and 33% with mCR. Notably, responses were also achieved in previously treated patients: 35% ORR, 38% any HI, and 67% mCR [66].

Extended Dosing of Oral Azacitidine in Patients With Lower Risk MDS
Approximately two-thirds of newly diagnosed patients with MDS present with lower risk disease (IPSS low or Int-1 risk) [19]. Lower risk patients are generally viewed as having favorable prognoses, with a median OS of 5.7 years for low-risk and 3.5 years for Int-1 risk disease [19]. However, a subgroup within the lower risk MDS population actually has a worse prognosis, with shortened survival time and clonal evolution to AML [68]. Approximately one-third of patients with lower risk MDS were shown to have poor prognostic features, with a median OS of only 1.2 years [68], the same as that reported for patients with Int-2 risk disease [19]. Severe anemia and thrombocytopenia

Table 2. Hematologic responses in patients with MDS, CMML, or AML treated with 1 cycle of s.c. azacitidine followed by oral azacitidine (CC-486) in 7-day dosing schedules [66]

Response	First-line-treated patients		Previously treated patients ^a		Total	
	EP, n	R, n (%)	EP, n	R, n (%)	EP, n	R, n (%)
Overall response ^b	15	11 (73)	17	6 (35)	32	17 (53)
CR ^c	15	6 (40)	17	0	32	6 (19)
Any HI	9	5 (56)	16	6 (38)	25	11 (44)
HI-E	4	2 (50)	10	3 (30)	14	5 (36)
HI-P	6	2 (33)	14	5 (36)	20	7 (35)
HI-N	7	2 (29)	10	0	17	2 (12)
mCR ^d	6	2 (33)	9	6 (67)	15	8 (53) ^e
TI	3	1 (33)	5	0	8	1 (13)
RBC	3	1 (33)	3	0	6	1 (17)
Platelet	0	0	4	0	4	0

^aIncludes erythropoiesis-stimulating agents, chemotherapy, hypomethylating agents, and investigational and/or other agents.

^bDoes not include patients with mCR only.

^cPatients achieving CR were not included in other categories.

^dTwo patients with mCR in the first-line group also had HI (HI-P [*n* = 1] and HI-E and HI-N [*n* = 1]) and 1 patient with mCR in the previously treated group also had HI (both HI-E and HI-P); these patients were included in the mCR and HI categories.

^eIn the 8 patients with mCR, the response began in cycle 1 of s.c. dosing (*n* = 4) or very early in cycle 2 of CC-486 dosing (*n* = 4); therefore, a single cycle of azacitidine s.c. likely contributed to the response.

Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; CR, complete response; E, erythroid; EP, evaluable patients; HI, hematologic improvement; mCR, marrow complete response; MDS, myelodysplastic syndromes; N, neutrophil; P, platelet; R, responders; RBC, red blood cell; s.c., subcutaneous; TI, transfusion independence.

are common poor prognostic features in patients with lower risk MDS [19, 68].

Although part 2 of AZA PH US 2007 CL 005 was initially designed to investigate extended dosing schedules of oral azacitidine (300 mg QD or 200 mg twice daily [BID] for 14 or 21 days per 28-day cycle) in patients with MDS, CMML, or AML (Fig. 2) [57], because of the new prognostic information about lower risk MDS, the trial was amended to focus on patients with lower risk MDS with poor prognostic features (low platelet count and/or low hemoglobin and/or RBC transfusion dependence [TD] and/or platelet TD). Part 2 included 53 patients with IPSS low-risk (28%) or Int-1 risk (72%) MDS; most patients were RBC-TD [69] (Table 1). Extended dosing with oral azacitidine (300 mg QD for 14 or 21 days of repeated 28-day cycles) resulted in response (IWG 2006 criteria [22]) in more than one-third of patients with lower risk MDS (Tables 1, 3), and the rate of RBC-TI increased from baseline with increasing cycles of treatment. The most common nonhematologic AEs were gastrointestinal, and there were no unexpected AEs based on the known safety profile of injectable azacitidine [32, 38, 69]. Eight patients (four in each arm) discontinued due to an AE. The most common grade 3/4 AEs ($\geq 10\%$) were neutropenia (8% and 19%, respectively), pneumonia (15% and 4%), anemia (12%

Table 3. Hematologic responses in patients with IPSS lower-risk MDS treated with oral azacitidine (CC-486) in extended dosing regimens [69]

Response	300 mg QD × 14 days		300 mg QD × 21 days		Total	
	EP, n	R, n (%)	EP, n	R, n (%)	EP, n	R, n (%)
Overall response ^a	26	11 (42)	27	10 (37)	53	21 (40)
Any HI	26	7 (27)	27	8 (30)	53	15 (28)
HI-E	23	4 (17)	25	6 (24)	48	10 (21)
HI-P	17	4 (24)	15	3 (20)	32	7 (22)
HI-N	10	3 (30)	6	0	16	3 (19)
RBC-TI						
Sustained 56 days	15	8 (54)	15	6 (40)	30	14 (47)
Sustained 84 days	15	3 (20)	15	5 (33)	30	8 (27)

^aComplete response, partial response, any HI, and TI by International Working Group 2006 criteria.

Abbreviations: E, erythroid; EP, evaluable patients; HI, hematologic improvement; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndromes; N, neutrophil; P, platelet; QD, once daily; R, responders; RBC, red blood cell; TI, transfusion independence.

and 7%), thrombocytopenia (12% and 4%), diarrhea (8% and 11%), and febrile neutropenia (4% and 11%) [69].

Preliminary data in patients with MDS, CMML, and AML suggest that oral azacitidine in extended dosing regimens may be associated with significant DNA hypomethylation through cycle end; however, this correlation must be confirmed in a larger patient population.

Oral Azacitidine in Patients With AML

IC is not appropriate for all patients with AML, and eligibility is influenced by age, performance status, comorbidities, and preexisting MDS [27–29, 70]. There is an unmet need for effective treatment options for patients who are ineligible or unwilling to receive IC [29]. Data from patients with AML in parts 1 and 2 of AZA PH US 2007 CL 005 were pooled (*n* = 23; 13 patients with de novo disease and 10 secondary to MDS) to assess response (IWG 2003 [45] and 2006 criteria [22]) to oral azacitidine [71] (Table 1). At baseline, 52% and 35% of patients had intermediate and unfavorable cytogenetics, respectively; 61% and 35% of patients were RBC-TD and platelet-TD, respectively; and 57% of patients were relapsed or refractory to prior treatment [71]. Of 8 patients treated with oral azacitidine at 120–600 mg QD for 7 days, 3 achieved a response (38%), including 1 with HI, 1 with RBC-TI, 2 with mCR, and 1 with marrow PR. Of 15 patients treated with oral azacitidine in extended dosing schedules (300 mg QD or 200 mg BID for 14 or 21 days), 7 achieved a response (47%), including 4 with HI, 4 with RBC-TI, 1 with platelet-TI, and 3

with marrow PR [71]. No patients with AML achieved CR or PR. The most common AEs were gastrointestinal, and 6 patients discontinued due to an AE. The most common grade 3/4 AEs (7-day and extended dosing regimens combined, $\geq 10\%$) were febrile neutropenia (35%), pneumonia (17%), syncope (17%), and nausea (13%) [71].

PK and PD of Oral Azacitidine

For patients with MDS, CMML, or AML in the AZA PH US 2007 CL 005 study, the maximum concentration ($C_{\max}$) of oral azacitidine occurred at 1.0 hour (range: 0.3–3.6 hours) after dosing, with a mean half-life of 0.6 hour [66]. In patients with lower risk MDS, oral azacitidine 300 mg QD for 14 or 21 days had a mean exposure per cycle of 38% and 56%, respectively, of that of s.c. azacitidine 75 mg/m² QD for 7 days (the approved dosing regimen) [72]. Exposure generally increased with dose, and no drug accumulation was observed following multiple administrations.

In patients evaluated for DNA methylation, 7-day dosing with s.c. azacitidine or oral azacitidine resulted in maximal decreases in highly methylated DNA loci at day 15 that returned to near-baseline levels by cycle end [66, 72]. Preliminary data in patients with MDS, CMML, and AML suggest that oral azacitidine in extended dosing regimens may be associated with significant DNA hypomethylation through cycle end [72]; however, this correlation must be confirmed in a larger patient population. The use of hypomethylation to predict response to hypomethylating agents remains controversial [73]. Other potential biomarkers for azacitidine response actively being investigated include mutations in *TET2* and *IDH1/2*, which are involved in DNA methylation [74–76].

Two phase I studies in patients with MDS, CMML, or AML evaluated the PK of immediate-release, enteric-coated, and capsule formulations of oral azacitidine and the effect of food and gastric pH alterations with concomitant administration of proton-pump inhibitors (PPIs) on PK parameters ($n = 47$) [67]. An immediate-release formulation was chosen for upcoming studies because it had the greatest mean oral bioavailability relative to s.c. azacitidine. PK parameters were similar under fasting and postprandial conditions; $C_{\max}$ was delayed by ~ 0.5 hour, and time to reach $C_{\max}$ was significantly delayed from 1.0 hour to 2.0 hours ($p < .05$) under postprandial conditions. Coadministration of the PPI omeprazole did not significantly affect PK parameters [67]. The lack of food effect or need for dose adjustments with PPIs allows for convenient administration of oral azacitidine.

KEY ONGOING OR PLANNED TRIALS OF ORAL AZACITIDINE (CC-486) IN MDS AND AML

Promising results of the expanded phase I program for oral azacitidine in MDS and AML led to the initiation of several additional studies, including two ongoing phase III trials.

QUAZAR Lower Risk MDS (AZA-MDS-003) Study

No currently approved therapies have demonstrated significantly prolonged survival in patients with lower risk MDS with thrombocytopenia and TD anemia. An alternative-dosing study of injectable azacitidine in patients with MDS

(most with lower-risk disease) suggested that prolonged exposure to a lower dose of azacitidine may benefit patients with multiple cytopenias [40]. The phase III QUAZAR Lower Risk MDS (AZA-MDS-003) study (ClinicalTrials.gov identifier NCT01566695) has a planned enrollment of 386 patients with RBC-TD anemia (average of ≥ 2 RBC units per 28 days, confirmed for ≥ 84 days immediately preceding randomization) and thrombocytopenia (2 platelet counts $\leq 75 \times 10^9/L$ ≥ 21 days apart) due to IPSS lower risk MDS [77]. This study will assess the efficacy of oral azacitidine (300 mg QD for 21 days of 28-day cycles) plus BSC versus placebo plus BSC in these patients. Enrolled patients must have MDS (WHO 2008 classification; excludes secondary MDS unless patients received their last dose of prior antineoplastic therapy ≥ 24 weeks prior to randomization), have Eastern Cooperative Oncology Group (ECOG) performance status 0–2, have no prior treatment with hypomethylating agents, have no prior treatment with lenalidomide within 24 weeks prior to randomization, and be SCT ineligible with no prior transplant. The primary outcome of interest is RBC-TI, with key secondary outcomes of survival, progression to AML, platelet-TI, hematologic response, platelet HI, erythroid HI, safety, health-related QOL (HRQOL), and health care resource utilization [77].

An alternative-dosing study of injectable azacitidine in patients with MDS (most with lower risk disease) suggested that prolonged exposure to a lower dose of azacitidine may benefit patients with multiple cytopenias.

QUAZAR AML Maintenance (CC-486-AML-001) Study

Most patients with AML currently will relapse following achievement of remission with IC, and it has been shown that duration of first remission is predictive of response to salvage therapies and long-term outcomes [78]. To improve outcomes, there is a need to prolong remissions, particularly in patients unable or unwilling to receive SCT. The phase III QUAZAR AML Maintenance (CC-486-AML-001) study (ClinicalTrials.gov identifier NCT01757535) has a planned enrollment of 460 patients (aged ≥ 55 years) with newly diagnosed (de novo or secondary) AML [79]. This study will assess the efficacy of oral azacitidine (300 mg QD for 14 days of 28-day cycles) plus BSC versus placebo plus BSC as maintenance therapy. All patients must be in first CR or CR with incomplete blood count recovery (CRi) after induction with or without consolidation therapy, have ECOG performance status 0–3, have not had prior CR/CRi with hypomethylating agents, and have not had prior transplant [79]. The primary outcome of interest is OS. Key secondary outcomes are relapse-free survival, CR/CRi, safety and tolerability, HRQOL, and health care resource utilization.

QUAZAR Post-Transplant Study

SCT remains the only potentially curative treatment option for patients with MDS or AML [27, 80, 81]; however, despite patients undergoing SCT, MDS and AML relapses are observed

in ~40% of patients [82–85]. Consequently, low-dose oral azacitidine is being investigated as post-transplant maintenance therapy. The phase I/II CC-486-AML-002 study (ClinicalTrials.gov identifier NCT01835587) will examine the role of oral azacitidine maintenance (3 + 3 design with 4 dosing cohorts: 200 or 300 mg QD on days 1–7 or 200 or 300 mg QD on days 1–14 of 28-day cycles) following SCT in ~30 patients with MDS or AML [86]. Positive results will provide support for a phase III QUAZAR post-transplant study. All patients must be 42–84 days after SCT, with an ECOG performance status 0–2 and no prior treatment with chemotherapies, investigational agents, hypomethylating agents, lenalidomide, thalidomide, or pomalidomide following SCT. The primary outcome of interest is MTD. Key secondary outcomes are safety, PK, and preliminary efficacy [86].

Oral azacitidine is also under investigation in selected solid tumors as a priming agent before chemotherapy or in combination with chemotherapy or immunotherapies.

CONCLUSION

Injectable azacitidine prolongs survival, reduces transfusions, and improves QOL for patients with higher risk MDS and AML compared with CCR; however, there is an unmet need for additional low-intensity treatment options for patients with MDS or AML, including those with lower risk MDS with additional poor prognostic factors. In addition to maximizing convenience and avoiding injection-site reactions, oral administration enables exploration of longer term dosing schedules that may prolong therapeutic effects of azacitidine by increasing exposure to cycling malignant cells. Oral azacitidine has been generally well tolerated, with a safety profile in line with what would be expected based on the well-established safety profile of injectable azacitidine. Although the MTD of

oral azacitidine was 480 mg QD on days 1–7 of a 28-day cycle, lower doses were more tolerable and allowed for extended low-dose administration over periods of 14 or 21 days. These schedules in 28-day cycles were biologically and clinically active in patients with MDS or AML. Ongoing and planned studies will more clearly define the future role of oral azacitidine as upfront or maintenance therapy in patients with MDS or AML.

ACKNOWLEDGMENTS

We thank Stacey Rose and Jennifer Leslie of MediTech Media for medical writing assistance in preparation of the outline and drafting of the manuscript and David Boffa for medical editing. Financial support for medical writing and editorial assistance was provided by Celgene Corporation.

AUTHOR CONTRIBUTIONS

Conception/Design: Christopher R. Cogle, Bart L. Scott, Thomas Boyd

Provision of study material or patients: Christopher R. Cogle, Bart L. Scott, Thomas Boyd

Collection and/or assembly of data: Christopher R. Cogle, Bart L. Scott, Thomas Boyd

Data analysis and interpretation: Christopher R. Cogle, Bart L. Scott, Thomas Boyd

Manuscript writing: Christopher R. Cogle, Bart L. Scott, Thomas Boyd

Final approval of manuscript: Christopher R. Cogle, Bart L. Scott, Thomas Boyd, Guillermo Garcia-Manero

DISCLOSURES

Christopher R. Cogle: Celgene (C/A, SAB); **Bart L. Scott:** Celgene, Novartis, Alexion (C/A), Alexion (H), Celgene (RF); **Thomas Boyd:** Genentech, US Oncology Research (RF), Celgene (H). The other author indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board

REFERENCES

- Walter MJ, Shen D, Ding L et al. Clonal architecture of secondary acute myeloid leukemia. *N Engl J Med* 2012;366:1090–1098.
- Papaemmanuil E, Gerstung M, Malcovati L et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood* 2013; 122:3616–3627; quiz 3699.
- Haferlach T, Nagata Y, Grossmann V et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia* 2014;28: 241–247.
- Woll PS, Kjällquist U, Chowdhury O et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. *Cancer Cell* 2014;25:794–808.
- Cazzola M, Malcovati L. Myelodysplastic syndromes—coping with ineffective hematopoiesis. *N Engl J Med* 2005;352:536–538.
- Heaney ML, Golde DW. Myelodysplasia. *N Engl J Med* 1999;340:1649–1660.
- Schanz J, Tüchler H, Solé F et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. *J Clin Oncol* 2012;30: 820–829.
- NCCN clinical practice guidelines in oncology (NCCN Guidelines®): Myelodysplastic syndromes, version 1.2016. Available at http://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed September 23, 2015.
- Challen GA, Sun D, Jeong M et al. Dnmt3a is essential for hematopoietic stem cell differentiation. *Nat Genet* 2012;44:23–31.
- Walter MJ, Ding L, Shen D et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. *Leukemia* 2011;25:1153–1158.
- Ko M, Bandukwala HS, An J et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. *Proc Natl Acad Sci USA* 2011;108:14566–14571.
- Ma X, Does M, Raza A et al. Myelodysplastic syndromes: Incidence and survival in the United States. *Cancer* 2007;109:1536–1542.
- Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood* 2012;120: 2454–2465.
- Previous version: SEER cancer statistics review, 1975–2011. Available at http://seer.cancer.gov/csr/1975_2011/. Accessed January 13, 2015.
- Sant M, Allemani C, Tereanu C et al. Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. *Blood* 2010;116:3724–3734.
- Cogle CR, Craig BM, Rollison DE et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: High number of uncaptured cases by cancer registries. *Blood* 2011;117: 7121–7125.
- Craig BM, Rollison DE, List AF et al. Under-reporting of myeloid malignancies by United States cancer registries. *Cancer Epidemiol Biomarkers Prev* 2012;21:474–481.
- Cogle CR, Iannacone MR, Yu D et al. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. *Leuk Res* 2014;38:71–75.
- Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood* 1997;89: 2079–2088.
- Malcovati L, Della Porta MG, Strupp C et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). *Haematologica* 2011;96:1433–1440.
- Cheson BD, Bennett JM, Kantarjian H et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. *Blood* 2000;96:3671–3674.
- Cheson BD, Greenberg PL, Bennett JM et al. Clinical application and proposal for modification of

the International Working Group (IWG) response criteria in myelodysplasia. *Blood* 2006;108:419–425.

23. Liesveld JL, Lichtman MA. Acute myelogenous leukemia. In: Lichtman MA, ed. *Williams Hematology*, 7th ed. New York, NY: McGraw-Hill, 2005: 1183–1236.
24. Licht JD, Sternberg DW. The molecular pathology of acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program* 2005;137–142.
25. Welch JS, Ley TJ, Link DC et al. The origin and evolution of mutations in acute myeloid leukemia. *Cell* 2012;150:264–278.
26. Thein MS, Ershler WB, Jemal A et al. Outcome of older patients with acute myeloid leukemia: An analysis of SEER data over 3 decades. *Cancer* 2013; 119:2720–2727.
27. Döhner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European Leukemia-Net. *Blood* 2010;115:453–474.
28. Milligan DW, Grimwade D, Cullis JO et al. Guidelines on the management of acute myeloid leukaemia in adults. *Br J Haematol* 2006;135: 450–474.
29. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: A review. *Br J Haematol* 2011;152:524–542.
30. Harousseau JL. Acute myeloid leukemia in the elderly. *Blood Rev* 1998;12:145–153.
31. Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. *J Clin Oncol* 2010;28:562–569.
32. Vidaza (azacitidine for injection) [package insert]. Summit, NJ: Celgene Corporation; 2014.
33. Dacogen (decitabine) [package insert]. Tokyo, Japan: Eisai Inc; 2010.
34. Raj K, Mufti GJ. Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes. *Ther Clin Risk Manag* 2006;2:377–388.
35. Hollenbach PW, Nguyen AN, Brady H et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. *PLoS One* 2010; 5:e9001.
36. Kaminskas E, Farrell AT, Wang YC et al. FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension. *The Oncologist* 2005;10:176–182.
37. Glover AB, Leyland-Jones B. Biochemistry of azacitidine: A review. *Cancer Treat Rep* 1987;71: 959–964.
38. Vidaza (azacitidine for injection) [package insert]. Uxbridge, U.K.: Celgene Europe; 2015.
39. García-Delgado R, de Miguel D, Bailén A et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. *Leuk Res* 2014;38:744–750.
40. Lyons RM, Cosgriff TM, Modi SS et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. *J Clin Oncol* 2009;27:1850–1856.
41. Martin MG, Walgren RA, Procknow E et al. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. *Am J Hematol* 2009;84:560–564.
42. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. *J Clin Oncol* 2002;20:2429–2440.
43. Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomized, open-label, phase III study. *Lancet Oncol* 2009;10:223–232.
44. Gore SD, Fenaux P, Santini V et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. *Haematologica* 2013;98: 1067–1072.
45. Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol* 2003;21:4642–4649.
46. Silverman LR, Fenaux P, Mufti GJ et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. *Cancer* 2011;117:2697–2702.
47. Sekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes. *Blood* 2014;123:829–836.
48. Duong VH, Lin K, Reljic T et al. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. *Clin Lymphoma Myeloma Leuk* 2013;13:711–715.
49. Nazha A, Sekeres MA, Garcia-Manero G et al. Outcomes of patients with myelodysplastic syndromes (MDS) who achieve stable disease after treatment with hypomethylating agents. *Blood* 2014;124:3273a.
50. Borthakur G, Ahdab SE, Ravandi F et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. *Leuk Lymphoma* 2008;49:690–695.
51. Prébet T, Gore SD, Esterni B et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. *J Clin Oncol* 2011;29:3322–3327.
52. Braun T, Cherait A, Berthon C et al. Treatment with decitabine (DAC) after azacitidine (AZA) failure in high risk myelodysplastic syndrome (MDS) and advanced chronic myelomonocytic leukemia (CMML). *Blood* 2013;122:2796a.
53. Bhatnagar B, Zandberg DP, Vannorsdall EJ et al. Lack of response of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) to decitabine after failure of azacitidine. *Blood* 2012; 120:3858a.
54. Santini V, Fenaux P, Mufti GJ et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. *Eur J Haematol* 2010;85: 130–138.
55. Dombret H, Seymour JF, Butrym A et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. *Blood* 2015;126: 291–299.
56. Garcia-Manero G, Stoltz ML, Ward MR et al. A pilot pharmacokinetic study of oral azacitidine. *Leukemia* 2008;22:1680–1684.
57. Garcia-Manero G, Gore SD, Cogle CR et al. Evaluation of oral azacitidine using extended treatment schedules: A phase I study. *Blood* 2010; 116:603a.
58. Chitambar CR, Libnoch JA, Matthaues WG et al. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. *Am J Hematol* 1991;37:100–104.
59. Saiki JH, Bodey GP, Hewlett JS et al. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: A Southwest Oncology Group Study. *Cancer* 1981;47:1739–1742.
60. Saiki JH, McCredie KB, Vietti TJ et al. 5-Azacytidine in acute leukemia. *Cancer* 1978;42:2111–2114.
61. Von Hoff DD, Slavik M, Muggia FM. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. *Ann Intern Med* 1976;85:237–245.
62. Pali SS, Van Emburgh BO, Sankpal UT et al. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. *Mol Cell Biol* 2008;28:752–771.
63. Lu LJ, Randerath K. Long term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo. *Mol Pharmacol* 1984;26:594–603.
64. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. *Ann Intern Med* 2001;134: 573–586.
65. Marcucci G, Silverman L, Eller M et al. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. *J Clin Pharmacol* 2005;45:597–602.
66. Garcia-Manero G, Gore SD, Cogle C et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. *J Clin Oncol* 2011;29:2521–2527.
67. Laille E, Savona MR, Scott BL et al. Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. *J Clin Pharmacol* 2014;54:630–639.
68. Garcia-Manero G, Shan J, Faderl S et al. A prognostic score for patients with lower risk myelodysplastic syndrome. *Leukemia* 2008;22: 538–543.
69. Garcia-Manero G, Gore SD, Kambhampati S et al. Safety and efficacy of oral azacitidine (CC-486) administered in extended treatment schedules to patients with lower-risk myelodysplastic syndromes. *Blood* 2012;120:424a.
70. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): Acute myeloid leukemia, version 1.2015. Available at http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed September 23, 2015.
71. Gore SD, Cogle CR, Skikne B et al. Oral azacitidine (AZA) activity in patients with acute myelogenous leukemia (AML). *Blood* 2011;118:1546a.
72. Laille E, Shi T, Garcia-Manero G et al. Extended dosing of oral azacitidine (CC-486) for 14 and 21 days provides more effective methylation reversal than a 7-day schedule. *Blood* 2012;120:1337a.
73. Voso MT, Santini V, Fabiani E et al. Why methylation is not a marker predictive of response to hypomethylating agents. *Haematologica* 2014; 99:613–619.

74. Itzykson R, Kosmider O, Cluzeau T et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. *Leukemia* 2011;25:1147–1152.
75. Bejar R, Lord A, Stevenson K et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. *Blood* 2014;124:2705–2712.
76. Emadi A, Faramand R, Carter-Cooper B et al. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. *Am J Hematol* 2015;90:E77–E79.
77. The efficacy and safety of oral azacitidine plus best supportive care versus placebo and best supportive care in subjects with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia due to International Prognostic Scoring System (IPSS) low risk myelodysplastic syndrome (MDS). Available at <http://www.clinicaltrials.gov/ct2/show/NCT01566695>. Accessed January 12, 2015.
78. Szer J. The prevalent predicament of relapsed acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program* 2012;2012:43–48.
79. Efficacy of oral azacitidine plus best supportive care as maintenance therapy in subjects with acute myeloid leukemia in complete remission (QUAZAR AML-001). Available at <http://www.clinicaltrials.gov/ct2/show/NCT01757535>. Accessed January 12, 2015.
80. Fey MF, Dreyling M. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010;21(suppl 5):v158–v161.
81. Scott BL, Deeg HJ. Myelodysplastic syndromes. *Annu Rev Med* 2010;61:345–358.
82. Kumar L. Leukemia: Management of relapse after allogeneic bone marrow transplantation. *J Clin Oncol* 1994;12:1710–1717.
83. Alessandrino EP, Della Porta MG, Bacigalupo A et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). *Blood* 2008;112:895–902.
84. Lim Z, Brand R, Martino R et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. *J Clin Oncol* 2010;28:405–411.
85. Sierra J, Pérez WS, Rozman C et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. *Blood* 2002;100:1997–2004.
86. Safety study of oral azacitidine (CC-486) as maintenance therapy after allogeneic hematopoietic stem cell transplantation in subjects with acute myeloid leukemia or myelodysplastic syndromes. Available at <http://www.clinicaltrials.gov/ct2/show/NCT01835587>. Accessed January 12, 2015.

For Further Reading:

Aziz Nazha, Mikkael A. Sekeres, Steven D. Gore et al. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? *The Oncologist* 2015;20:1069–1076.

Implications for Practice:

Heterogeneity in clinical outcomes of MDS is partly related to interpatient variability of recurrent somatic mutations that drive disease phenotype and progression. Although clinical risk stratification tools have functioned well in prognostication for patients with MDS, their ability to predict clinical benefits of specific MDS therapies is limited. Molecular testing shows promise in aiding diagnosis, risk stratification, and therapy-specific benefit prediction for MDS patients. Nonetheless, logistical issues related to assay performance standardization, validation, interpretation, and development of guidelines for how to use the results to inform clinical decisions are yet to be resolved.